|
Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes ‘encouraging’ preclincal data for RXC004 as a targeted therapy for Wnt-ligand driven cancer.
Redx Pharma explains that RXC004 is currently being evaluated as monotherapy in phase two trials in patients with pancreatic cancer, metastatic colorectal cancer and biliary cancer. Data from this trial is expected in 2023.
‘This preclinical data further underpins our excitement around the therapeutic potential of RXC004, and the role of effective Wnt pathway blockade, in tackling a number of difficult to treat cancers with high unmet need,’ said Jane Robertson, chief medical officer at Redx Pharma.
Current stock price: 71.00 pence
12-month change: up 5.2%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
